LigaChem Biosciences will attend the 44th JP Morgan Healthcare Conference (JPM 2026), the world's largest pharmaceutical and biotech investment event, to be held in San Francisco from the 12th to the 15th (local time), after receiving an official invitation.
LigaChem Biosciences said on the 6th that at this conference it will present its antibody-drug conjugate (ADC) development platform and new drug candidates to global big pharma companies and proceed with technology transfer discussions.
An ADC is a treatment technology that delivers a drug attached to an antibody precisely to cancer cells only. It consists of an "antibody" that seeks out cancer cells, a drug called a "payload" that kills cancer cells, and a "linker" that connects them.
At this event, the company plans to deepen partnering discussions with pharmaceutical companies worldwide based on the global clinical results of its R&D pipeline built on its ConjuALL platform. This is a linker (connector) technology that conjugates the desired amount of drug to specific sites on an antibody.
The company said it is drawing market attention as clinical data from major pipelines recently out-licensed have shown strong results. In the global phase 1 trial of IKS014 (LCB14), a HER2 (human epidermal growth factor receptor 2)-targeting ADC, it demonstrated excellent efficacy and safety. CS5001 (LCB71), a ROR1-targeting ADC, proved efficacy not only in hematologic malignancies but also in solid tumors for the first time among ROR1 ADCs, earning evaluations that it is superior compared with rival drugs.
A company official said, "Inquiries from global corporations hoping to adopt ADC platform technology and new drug candidates have surged compared with last year," and added, "At this event, we expect active discussions on partnerships not only for follow-up meetings with partnering candidate companies but also with new big pharma companies seeking to adopt the platform."
LigaChem Biosciences also said it plans to actively promote the value of newly developed ADC linkers and payloads, including the competitiveness of its proprietary payload technology, the PBD prodrug, and next-generation payloads that overcome resistance issues of topoisomerase I inhibitor–based payloads. Park Se-jin, LigaChem Biosciences Chief Operating Officer (COO), said, "We will do our best to accelerate the multiple ongoing technology transfer discussions through this event and turn them into tangible results."